en
Scientific article
English

Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Published inJournal of thrombosis and haemostasis, vol. 13, no. 4, p. 520-529
Publication date2015
Abstract

Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.

Keywords
  • Adult
  • Coagulants/administration & dosage/adverse effects/therapeutic use
  • Compassionate Use Trials
  • Dinoprostone/analogs & derivatives/therapeutic use
  • Drug Administration Schedule
  • Factor VIII/administration & dosage/adverse effects/therapeutic use
  • Female
  • France
  • Hemostatic Techniques/adverse effects
  • Humans
  • Hysterectomy
  • Infusions, Intravenous
  • Postpartum Hemorrhage/diagnosis/drug therapy/mortality
  • Pregnancy
  • Risk Factors
  • Severity of Illness Index
  • Switzerland
  • Time Factors
  • Treatment Failure
  • Venous Thrombosis/chemically induced
Citation (ISO format)
LAVIGNE-LISSALDE, G et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. In: Journal of thrombosis and haemostasis, 2015, vol. 13, n° 4, p. 520–529. doi: 10.1111/jth.12844
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1538-7836
367views
0downloads

Technical informations

Creation10/31/2016 1:24:00 PM
First validation10/31/2016 1:24:00 PM
Update time03/15/2023 1:04:00 AM
Status update03/15/2023 1:03:59 AM
Last indexation01/16/2024 10:32:38 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack